NCT05326295 Evaluation of Treatment Efficacy by Circulating Tumor Cell Phenotype Surveillance in Breast Cancer Patients
| NCT ID | NCT05326295 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hunan Cancer Hospital |
| Condition | Breast Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2019-03-01 |
| Primary Completion | 2028-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2019-03-01 with a primary completion date of 2028-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The phenotype of circulating tumor cells (CTCs) is supposed to be significant indicator that is correlated the prognosis of breast cancer patients who have completed neoadjuvant chemotherapy, primary tumor surgery with/without adjuvant chemotherapy. The aim of this observational study is to assess the efficacy of CTCs surveillance in predicting the prognosis of breast cancer patients.
Eligibility Criteria
Inclusion Criteria * The age is more than 18 years old; * Pathology confirmed malignant breast tumor; * No clinical diagnosis of other malignancies, unstable complications or uncontrolled infection; * Life expectancy is greater than 6 month; * The main organ function is normal; * The subjects volunteered to participate in this study, signed informed consent, followed up with good compliance. Exclusion Criteria * Patients who had suffered from other malignant tumors; * With uncontrolled bacterial, viral or fungal infections; * With physical or mental disorders * Without or limited civil capacity; * Infected with human immunodeficiency virus (HIV)； * Circumstances in which the investigator considers it inappropriate to participate in this study.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05326295 clinical trial?
This trial is open to female participants only, aged 18 Years or older, up to 75 Years, studying Breast Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05326295 currently recruiting?
Yes, NCT05326295 is actively recruiting participants. Contact the research team at oyqc1969@126.com for enrollment information.
Where is the NCT05326295 trial being conducted?
This trial is being conducted at Changsha, China.
Who is sponsoring the NCT05326295 clinical trial?
NCT05326295 is sponsored by Hunan Cancer Hospital. The trial plans to enroll 1,000 participants.